gil j van lunsen executive profile  biography  bloomberg july    pm et biotechnology company overview of array biopharma inc snapshotpeople  overviewboard memberscommittees executive profile gil j van lunsen director array biopharma incagetotal calculated compensationthis person is connected to  board members in  different organizations across  different industriessee board relationships background mr gil j van lunsen served as managing partner of kpmg llp and led its tulsa oklahoma office since  mr van lunsen retired from kpmg llp in june  following  years of service nine years after joining kpmg in  as an assistant accountant he became partner and subsequently was promoted to partner in charge of national accounting and audit training he transferred to the tulsa oklahoma office in july  he served as the chairman of the board of trustees  of both the childrens medical center and tulsa regional medical center in tulsa he has been a director of array biopharma inc since october  he serves as a director of northern border partners lp and viking gas transmission company he has been an independent director of macom technology solutions holdings inc and macom technology solutions inc since august  he was elected to the partnership in  he has been an independent director of macom technology solutions inc and macom technology solutions holdings inc since august  he served as a director oneok partners gp llc general partner of oneok partners lp from may  to april   van lunsen served as a director at sirenza microdevices inc since october   oneok inc since april  hillcrest healthcare systems from july  to march  and vl dissolution corp since june   additionally he was a member of the ethics compliance committee of tyson foods inc from january  to december  he served as the chairman of audit committee at both hillcrest healthcare system in tulsa oklahoma and vari l company inc in denver colorado his professional affiliations include the american institute of certified public accountants and the colorado society of certified public accountants mr van lunsen received his bsba in accounting and finance from the university of denver in  and is a certified public accountantread full background corporate headquarters  walnut streetboulder colorado united statesphone fax  board members memberships directorviking gas transmission companypresentdirectorarray biopharma incpresentindependent directormacom technology solutions incpresentindependent directormacom technology solutions holdings inc education bsba university of denver other affiliations sirenza microdevices inckpmg llpmacom technology solutions inconeok inconeok partners lpvl dissolution corpviking gas transmission companyoneok partners gp llcuniversity of denvermacom technology solutions holdings inc annual compensation there is no annual compensation data available stocks options there is no stock options data available total compensation total annual cash compensationtotal calculated compensation request profile update   the information and data displayed in this profile are created and managed by sp global market intelligence a division of sp global bloombergcom does not create or control the content for inquiries please contact sp global market intelligence directly by clicking here stock quotes market data is delayed at least  minutes company lookup competitor compensationnamepositioncompanycompensationamit d munshi president ceo  directorarena pharmaceuticals inckrobert i blum president ceo  directorcytokinetics incorporatedkjosé maría fernández sousafaro phdfounder executive chairman chief executive officer and presidentpharma mar sakrajesh c shrotriya mdchairman and chief executive officerspectrum pharmaceuticals incmmark r baker jdchief executive officer and directorprogenics pharmaceuticals inckcompensation as of fiscal year  sponsored financial commentaries sponsored links browse companies a b c d e f g h i j k l m n o p q r s t u v w x y z              request profile update only a company representative may request an update for the company profile documentation will be required to contact array biopharma inc please visit  company data is provided by sp global market intelligence please use this form to report any data issues information missing  please enter your information in the following fields company name your name your email address your phone number type of data overview executives key developments similar companies transactions update needed all data changes require verification from public sources please include the correct value or values and a source where we can verify cancel submit your requested update has been submitted our data partners will research the update request and update the information on this page if necessary research and followup could take several weeks if you have questions you can contact them at bwwebmasterbusinessweekcom close gil j van lunsen board dir array biopharma inc a publisher of business information since         search business search executive   advanced search   sign in    hints profile of gil van lunsen   gil van lunsen   board dir  array biopharma inc   gil van lunsen email  please login   company name  array biopharma inc   company website  wwwarraybiopharmacom   company address   walnut st boulder counited states   gil van lunsen profile  board dir  array biopharma inc   gil van lunsen biography  mr van lunsen has served as a member of our board of directors since october  prior to his retirement in june  mr van lunsen was a managing partner of kpmg llp and led the firm�s tulsa oklahoma office during his year career mr van lunsen held various positions of increasing responsibility with kpmg and was elected to the partnership in  mr van lunsen is currently the audit committee chairman at both hillcrest healthcare system in tulsa oklahoma and sirenza microdevices inc in broomfield colorado additionally mr van lunsen was a member on the ethics compliance committee for tyson foods inc from  until  and chaired the audit committee of varil company inc from  until  mr van lunsen received a bsba in accounting from the university of denver and is a certified public accountantas part of his responsibilities as an array board member mr van lunsen serves on arrays audit committee   gil van lunsen colleagues  name title email david snitman dir coo vp  business development please login john josey vp  discovery chemistry please login kyle lefkoff chmn please login kevin koch dir pres chief scientific officer please login marvin caruthers board dir please login             home    about us    product information     subscription    list builder     executive list     email lists     contact us    site map    browse directory      �  walkerss research  a publisher of business information since  all rights reserved mtsi gil j van lunsen insider trades for macom technology solutions holdings inc bulletin investor alert new york markets close in market snapshot winners and losers expand keep open close expand keep open close expand keep open close expand keep open close expand keep open close macom technology solutions holdings inc nasdaq mtsi go set alerts find a broker join td ameritrade market index overview profile news charts financials historical quotes analyst estimates options sec filings insiders marketstatecountryus macom technology solutions holdings inc market open  real time quotes jul    pm mtsi quoteszigmancomposite   change   volume volume  real time quotes quoteszigmancomposite previous close     change   day low day high    week low  week high   insider activity individual gil j van lunsen mr gil j van lunsen cpa is on the board of directors at macom technology solutions holdings inc and array biopharma inc mr van lunsen was previously employed as an independent director by oneok partners lp managing partner by kpmg llp an independent director by oneok partners gp llc and memberethics compliance committee by tyson foods inc he also served on the board at sirenza microdevices inc and hillcrest healthcare system inc he received his undergraduate degree from the university of denver transactions date shares transaction value     disposition at  per share      disposition at  per share      disposition at  per share      award at  per share      disposition at  per share      disposition at  per share      disposition at  per share      disposition at  per share      disposition at  per share      disposition at  per share      disposition at  per share      disposition at  per share      award at  per share      award at  per share      award at  per share      award at  per share      award at  per share      award at  per share      award at  per share  copyright  factset research systems inc all rights reserved source factset fundamentals officers and executives mr john l ocampo chairman mr john r croteau president chief executive officer  director mr robert dennehy senior vice presidentoperations mr robert j mcmullan cfo principal accounting officer  senior vp dr douglas j carlson vice presidenttechnology dr alex a behfar svp  general managerphotonic solutions mr preetinder s virk senior vice president  gmcarrier networks mr greg baker senior vice president gmrf  microwave mr jack kennedy senior vice president gmaerospace  defense ms susan m ocampo director mr dong hyun hwang senior vice presidentglobal sales mr william van anglen vice presidenthuman resources mr clay simpson secretary vice president  general counsel mr geoffrey g ribar independent director mr charles r bland independent director mr stephen g daly independent director mr gil j van lunsen independent director mr peter y chung independent director trending tickers quoteszigmancomposite vuzi quoteszigmancomposite jcp quoteszigmancomposite nugt quoteszigmancomposite jnug quoteszigmancomposite tlt x powered by log in  pm edt july   marketstatecountryus new york open marketstatecountryuk london closed marketstatecountryjp tokyo closed marketstatecountryus   marketstatecountryuk   marketstatecountryjp   view all latest news newslatest pwhite house briefs reporters after spicer quits as press secretary live blog pgold marks highest settlement in a month up over  for the week pspicer says in a tweet hell continue in job through august paugust gold climbs  or  to settle at oz pgold prices end at highest level in a month up over  for the week phollywood is using movies to push social causes — and vice versa peuropean stocks log worst daily drop in  weeks as euro rallies poil drops to a week low with opec output expected to rise phomesecurity company adt could go public by the end of the year pge’s stock falls as jeff immelt’s th and last quarter is another disappointment peuro rally has room to run if this pattern continues to hold true psean spicer just quit should you be next ppetiq shares soaring  in companys market debut pamazon’s foray into groceries means more mergers of food companies experts say pftse  ends lower but retains grip on weekly gain pbaker hughes data show us oilrig count down for first time in three weeks pstock market retreats as ge casts pall on earnings season ppetiq shares up  in companys market debut phoneywell upgraded to buy from hold at cfra pseptember wti oil trades at bbl vs  before the rig data loading more headlines dow quoteszigmanrealtime    nasdaq quoteszigmanrealtime    sp  quoteszigmanrealtime    kiosk   the retirementors retirement advice from our industry experts our team of financial professionals can help you plan and save for retirement then live well in it congakioskretirementorshtml    alerts congakioskalertshtml    virtual stock exchange our free stockmarket game • trade your virtual portfolio in real time • talk strategies in group discussions • find or create a game that suits you • use our learning center to improve congakioskgameshtml    location scouts housingmarket insights from our realty pros plus the latest data from realtorcom on  home markets across the us • see our complete real estate site congakioskrealestatehtml    lazy portfolios set it and forget it check out the returns on our  lazy portfolios that are made up of lowcost buyandhold index funds • how to create your own lazy portfolio congakiosklazyportfoliohtml  marketwatchcom site index topics help feedback newsroom roster media archive premium products mobile company info code of conduct corrections advertising media kit advertise locally reprints  licensing broker center your ad choices follow marketwatch rss podcasts wsjcom barrons online bigcharts virtual stock exchange financial news london wsjcom small business realtorcom mansion global copyright   marketwatch inc all rights reserved by using this site you agree to the terms of service privacy policy and cookie policy intraday data provided by six financial information and subject to terms of use historical and current endofday data provided by six financial information all quotes are in local exchange time realtime last sale data for us stock quotes reflect trades reported through nasdaq only intraday data delayed at least  minutes or per exchange requirements marketwatch top stories link to marketwatchs slice  arry gil j van lunsen insider trades for array biopharma inc bulletin investor alert new york markets close in market snapshot winners and losers expand keep open close expand keep open close expand keep open close expand keep open close expand keep open close array biopharma inc nasdaq arry go set alerts find a broker join td ameritrade market index overview profile news charts financials historical quotes analyst estimates options sec filings insiders marketstatecountryus array biopharma inc market open  real time quotes jul    pm arry quoteszigmancomposite   change   volume volume m real time quotes quoteszigmancomposite previous close     change   day low day high    week low  week high   insider activity individual gil j van lunsen mr gil j van lunsen cpa is independent director at macom technology solutions holdings inc and independent director at array biopharma inc he is on the board of directors at macom technology solutions holdings inc and array biopharma inc mr van lunsen was previously employed as independent director by oneok partners lp managing partner by kpmg llp independent director by oneok partners gp llc and a memberethics compliance committee by tyson foods inc he also served on the board at sirenza microdevices inc and hillcrest healthcare system inc he received his undergraduate degree from the university of denver transactions date shares transaction value     derivativenonderivative trans at  per share  copyright  factset research systems inc all rights reserved source factset fundamentals officers and executives mr ron squarer chief executive officer  director mr andrew r robbins chief operating officer mr jason haddock chief financial officer dr victor sandor chief medical officer dr nicholas a saccomano chief scientific officer ms shalini sharp director ms tricia haugeto directorcorporate communications  ir ms kimberly pope vice presidenthuman resources mr john r moore secretary vice president  general counsel mr kyle a lefkoff chairman dr charles m baum independent director mr john a orwin independent director dr gwen a fyfe independent director mr gil j van lunsen independent director trending tickers quoteszigmancomposite vuzi quoteszigmancomposite jcp quoteszigmancomposite nugt quoteszigmancomposite jnug quoteszigmancomposite tlt x powered by log in  pm edt july   marketstatecountryus new york open marketstatecountryuk london closed marketstatecountryjp tokyo closed marketstatecountryus   marketstatecountryuk   marketstatecountryjp   view all latest news newslatest pwhite house briefs reporters after spicer quits as press secretary live blog pgold marks highest settlement in a month up over  for the week pspicer says in a tweet hell continue in job through august paugust gold climbs  or  to settle at oz pgold prices end at highest level in a month up over  for the week phollywood is using movies to push social causes — and vice versa peuropean stocks log worst daily drop in  weeks as euro rallies poil drops to a week low with opec output expected to rise phomesecurity company adt could go public by the end of the year pge’s stock falls as jeff immelt’s th and last quarter is another disappointment peuro rally has room to run if this pattern continues to hold true psean spicer just quit should you be next ppetiq shares soaring  in companys market debut pamazon’s foray into groceries means more mergers of food companies experts say pftse  ends lower but retains grip on weekly gain pbaker hughes data show us oilrig count down for first time in three weeks pstock market retreats as ge casts pall on earnings season ppetiq shares up  in companys market debut phoneywell upgraded to buy from hold at cfra pseptember wti oil trades at bbl vs  before the rig data loading more headlines dow quoteszigmanrealtime    nasdaq quoteszigmanrealtime    sp  quoteszigmanrealtime    kiosk   the retirementors retirement advice from our industry experts our team of financial professionals can help you plan and save for retirement then live well in it congakioskretirementorshtml    alerts congakioskalertshtml    virtual stock exchange our free stockmarket game • trade your virtual portfolio in real time • talk strategies in group discussions • find or create a game that suits you • use our learning center to improve congakioskgameshtml    location scouts housingmarket insights from our realty pros plus the latest data from realtorcom on  home markets across the us • see our complete real estate site congakioskrealestatehtml    lazy portfolios set it and forget it check out the returns on our  lazy portfolios that are made up of lowcost buyandhold index funds • how to create your own lazy portfolio congakiosklazyportfoliohtml  marketwatchcom site index topics help feedback newsroom roster media archive premium products mobile company info code of conduct corrections advertising media kit advertise locally reprints  licensing broker center your ad choices follow marketwatch rss podcasts wsjcom barrons online bigcharts virtual stock exchange financial news london wsjcom small business realtorcom mansion global copyright   marketwatch inc all rights reserved by using this site you agree to the terms of service privacy policy and cookie policy intraday data provided by six financial information and subject to terms of use historical and current endofday data provided by six financial information all quotes are in local exchange time realtime last sale data for us stock quotes reflect trades reported through nasdaq only intraday data delayed at least  minutes or per exchange requirements marketwatch top stories link to marketwatchs slice    gil van lunsen   decypha sign in  welcome guest regions gcc  levant  mena  north africa gcc bahrain  kuwait  oman  qatar  saudi arabia  united arab emirates levant iraq  jordan  lebanon  palestine north africa egypt  libya  morocco  tunisia others iran  turkey  united kingdom  united states advanced search news markets companies research funds fixed income money markets commodities fx economics analysis more sign in membership customize your decypha logout welcome decypha alerts home people profiles people profile gil van lunsen profile full name gil van lunsen country biography gil van lunsen has served as a director since august  prior to his retirement in june  mr van lunsen was a managing partner of kpmg llp and designations date designation entity entity description country  array biopharma inc    oneok partners lp energy united states  macom technology solutions holdings inc   check all the individuals in check the list request a trial title select mr mrs ms miss dr prof first name last name job title select asset managers corporate banks investment managers wealth managers consultants  advisors legal practioners academics hedge funds private equity analysts traders equity research analysts phone company email country select afganistan albania algeria american samoa andorra angola anguilla antarctica antigua and barbuda argentina armenia aruba australia austria azerbaijan bahamas bahrain bangladesh barbados belarus belgium belize benin bermuda bhutan bolivia bosnia and herzegovina botswana bouvet island brazil british indian ocean territory brunei bulgaria burkina faso burundi cambodia cameroon canada cape verde cayman islands central african republic chad chile china christmas island cocos keeling islands colombia comoros congo cook islands costa rica cote divoire ivory coast croatia hrvatska cuba curacao cyprus czech republic czechoslovakia former denmark djibouti dominica dominican republic east timor ecuador egypt el salvador equatorial guinea eritrea estonia ethiopia falkland islands malvinas faroe islands fiji finland france france metropolitan french guiana french polynesia french southern territories gabon gambia georgia germany ghana gibraltar greece greenland grenada guadeloupe guam guatemala guernsey guinea guineabissau guyana haiti heard and mcdonald islands honduras hong kong hungary iceland india indonesia iran iraq ireland isle of man israel italy jamaica japan jersey jordan kazakhstan kenya kiribati kuwait kyrgyzstan laos latvia lebanon lesotho liberia libya liechtenstein lithuania luxembourg macau macedonia madagascar malawi malaysia maldives mali malta marshall islands martinique mauritania mauritius mayotte mexico micronesia moldova monaco mongolia montenegro montserrat morocco mozambique myanmar namibia nauru nepal netherlands netherlands antilles neutral zone new caledonia new zealand aotearoa nicaragua niger nigeria niue norfolk island north korea northern mariana islands norway oman pakistan palau palestine panama papua new guinea paraguay peru philippines pitcairn poland portugal puerto rico qatar reunion romania russia rwanda s georgia and s sandwich isls saint kitts and nevis saint lucia saint vincent and the grenadines samoa san marino sao tome and principe saudi arabia senegal serbia seychelles sierra leone singapore slovak republic slovenia solomon islands somalia south africa south korea south sudan spain sri lanka st helena st pierre and miquelon sudan suriname svalbard and jan mayen islands swaziland sweden switzerland syria taiwan tajikistan tanzania thailand togo tokelau tonga trinidad and tobago tunisia turkey turkmenistan turks and caicos islands tuvalu us minor outlying islands ussr former uganda ukraine united arab emirates united kingdom united states uruguay uzbekistan vanuatu vatican city state holy see venezuela vietnam virgin islands british virgin islands us wallis and futuna islands western sahara yemen yugoslavia zaire zambia zimbabwe comments required fields   submit already registered login attempt was not successful please try again username email password enter characters   login forget your password by job title asset managers  corporate banks  investment managers  wealth managers  consultants  advisors  legal practitioners  academics  hedge funds  private equity analysts  traders  equity research analysts by scope equity  fixed income  funds  excel  analytical tools  markets  prices  money market  news  industry  ipos  mergers  acquisitions  commodities  economics covered countries and exchanges add your company   add yourself   terms and conditions   privacy policy   about directfn copyright  directfn all rights reserved data not available login login attempt was not successful please try again username email password enter characters forget your password back to top support  feedback ask for free trial request a trial title mr mrs ms miss dr prof first name last name email phone promo code country select afganistan albania algeria american samoa andorra angola anguilla antarctica antigua and barbuda argentina armenia aruba australia austria azerbaijan bahamas bahrain bangladesh barbados belarus belgium belize benin bermuda bhutan bolivia bosnia and herzegovina botswana bouvet island brazil british indian ocean territory brunei bulgaria burkina faso burundi cambodia cameroon canada cape verde cayman islands central african republic chad chile china christmas island cocos keeling islands colombia comoros congo cook islands costa rica cote divoire ivory coast croatia hrvatska cuba curacao cyprus czech republic czechoslovakia former denmark djibouti dominica dominican republic east timor ecuador egypt el salvador equatorial guinea eritrea estonia ethiopia falkland islands malvinas faroe islands fiji finland france france metropolitan french guiana french polynesia french southern territories gabon gambia georgia germany ghana gibraltar greece greenland grenada guadeloupe guam guatemala guernsey guinea guineabissau guyana haiti heard and mcdonald islands honduras hong kong hungary iceland india indonesia iran iraq ireland isle of man israel italy jamaica japan jersey jordan kazakhstan kenya kiribati kuwait kyrgyzstan laos latvia lebanon lesotho liberia libya liechtenstein lithuania luxembourg macau macedonia madagascar malawi malaysia maldives mali malta marshall islands martinique mauritania mauritius mayotte mexico micronesia moldova monaco mongolia montenegro montserrat morocco mozambique myanmar namibia nauru nepal netherlands netherlands antilles neutral zone new caledonia new zealand aotearoa nicaragua niger nigeria niue norfolk island north korea northern mariana islands norway oman pakistan palau palestine panama papua new guinea paraguay peru philippines pitcairn poland portugal puerto rico qatar reunion romania russia rwanda s georgia and s sandwich isls saint kitts and nevis saint lucia saint vincent and the grenadines samoa san marino sao tome and principe saudi arabia senegal serbia seychelles sierra leone singapore slovak republic slovenia solomon islands somalia south africa south korea south sudan spain sri lanka st helena st pierre and miquelon sudan suriname svalbard and jan mayen islands swaziland sweden switzerland syria taiwan tajikistan tanzania thailand togo tokelau tonga trinidad and tobago tunisia turkey turkmenistan turks and caicos islands tuvalu us minor outlying islands ussr former uganda ukraine united arab emirates united kingdom united states uruguay uzbekistan vanuatu vatican city state holy see venezuela vietnam virgin islands british virgin islands us wallis and futuna islands western sahara yemen yugoslavia zaire zambia zimbabwe company job title select academics asset managers consultants  advisors corporate banks equity research analysts hedge funds investment managers legal practioners private equity analysts traders wealth managers comments required fields   submit contact us hello please use the below form for product support  feedback name   email  phone number   preferred contact method  email phone technical support x     slhopsdirectfnnet your account manager is   get a decypha membership to view this content get a decypha membership get the membership of decypha premium package to access more exciting features including advanced analytical tools and the pro  package pro  is designed keeping active investors in mind and offers a flexible framework to view information and do analysis the way you desire all you need to access these valuable features is to click on the get a membership button and submit your details to our sales team upgrade your membership account is not entitled to view this information please contact your account manager to upgrade your membership email  supportdecyphacom register to view this content decypha free registration register free with decypha and get access to realtime price information and many other features including technical scanner fundamental screener etc just click the registration button submit your details and get registered for free gil j van lunsen  executive bio compensation history and contacts  equilar atlas   log in  sign up x   as featured in gil j van lunsen board member at array biopharma inc view full profile are you gil j van lunsen claim your profile   sign up for equilar atlas and view gil j van lunsens full profile with equilar atlas you can identify corporate executives in gil j van lunsens network and community follow changes in gil j van lunsens employment and moneyinmotion connect with gil j van lunsen through your network of contacts gil j van lunsens executive work history current board member macom technology solutions holdings inc board member array biopharma inc past to view gil j van lunsens complete executive work history sign up now education bs university of denver age      gil j van lunsens biography gil van lunsen age  is a class i director who has served as a director since august  prior to his retirement in june  mr van lunsen was a managing partner of kpmg llp and led the firms tulsa oklahoma office during his year career mr van lunsen held various positions of increasing responsibility with kpmg llp and was elected partner in  mr van lunsen is currently a member of the board of directors and the audit committee chairman at array biopharma inc a biopharmaceutical company he served as a director and the chairman of the audit committee of oneok partners lp a natural gas gathering processing storage  read more gil van lunsen age  is a class i director who has served as a director since august  prior to his retirement in june  mr van lunsen was a managing partner of kpmg llp and led the firms tulsa oklahoma office during his year career mr van lunsen held various positions of increasing responsibility with kpmg llp and was elected partner in  mr van lunsen is currently a member of the board of directors and the audit committee chairman at array biopharma inc a biopharmaceutical company he served as a director and the chairman of the audit committee of oneok partners lp a natural gas gathering processing storage and transportation provider and its predecessor entities from  until his retirement in  previously mr van lunsen served as a director of sirenza and was chairman of its audit committee from october  through its sale to rfmd in november  mr van lunsen received a bsba in accounting from the university of denver mr van lunsen has extensive experience with complex financial and accounting issues and as a former partner of kpmg llp and the audit committee chairman at other public companies in our industry and others provides valuable leadership and insights to our board of directors on accounting financial and governance matters having served as a director of sirenza mr van lunsen has also developed strong domain knowledge of the operational and financial issues facing our company and our industry source macom technology solutions holdings inc on    sign up for equilar atlas and view gil j van lunsens full profile by accessing equilar atlas you can view bios network salary and wealth events of industryleading executives like gil j van lunsen more specifically youll be able to identify corporate executives in gil j van lunsens network and community follow changes in gil j van lunsens employment and moneyinmotion connect with gil j van lunsen through your network of conections view full profile   search for over  executive profiles bio example gil j van lunsen gil j van lunsens connections  sign up now to view gil j van lunsens  connections » gerald b smith board member eaton corporation plc liam ratcliffe former board member edge therapeutics inc ron squarer dir and chief executive officer array biopharma inc r m carruthers chief financial officer and interim president nivalis therapeutics inc david l snitman former consultant array biopharma inc michael n needle chief medical officer aveo pharmaceuticals inc john a orwin dir president and chief executive officer relypsa inc john l zabriskie former board member array biopharma inc caron a lawhorn senior vice president commercial one gas inc wesley j christensen senior vice president operations oneok inc popular profiles sign up now to view more executive profiles » john j kita evp and cfo a o smith elon r musk ceo and chairman tesla thomas j lynch executive chairman te connectivity ltd jan koum board member facebook inc robert d perlmutter senior evp and coo the macerich company × claim your profile coming soon interested in updating your biography and work history were working on making it happen well email you when this feature is available please enter valid email address done thank you for your interest ok browse executive profiles  a  b  c  d  e  f  g  h  i  j  k  l  m  n  o  p  q  r  s  t  u  v  w  x  y  z equilar homepage equilar atlas equilar insight equilar boardedge equilar engage research services knowledge network about us login �  equilar all rights reserved privacy policy  marshall street redwood city ca   phone    fax   secgems van lunsen gil j data feeds now available excel  csv  java  python etc database learn more van lunsen gil j info ownership filings ←    → ownership filings    of   total  filing date  submission nc form  ownership statement of changes in beneficial ownership insider trading  directors officers significant shareholders  issuer macom technology solutions holdings inc mtsi reporting owner van lunsen gil j  director  type title convexer price trans date deemed exe date trans form type trans code eqty swap footnote id trans timelines  shares value total value price  share acq or disp date exercisable expiration date  owned post trans value owned post trans underlying security title  underlying securities value underlying securities direct or indirect own nature indirect own nonderriv transcommon stocks  open market or private salefalsedd filing date  submission nc form  ownership statement of changes in beneficial ownership insider trading  directors officers significant shareholders  issuer macom technology solutions holdings inc mtsi reporting owner van lunsen gil j  director  type title convexer price trans date deemed exe date trans form type trans code eqty swap footnote id trans timelines  shares value total value price  share acq or disp date exercisable expiration date  owned post trans value owned post trans underlying security title  underlying securities value underlying securities direct or indirect own nature indirect own nonderriv transcommon stocks  open market or private salefalsedd filing date  submission nc form  ownership statement of changes in beneficial ownership insider trading  directors officers significant shareholders  issuer macom technology solutions holdings inc mtsi reporting owner van lunsen gil j  director  type title convexer price trans date deemed exe date trans form type trans code eqty swap footnote id trans timelines  shares value total value price  share acq or disp date exercisable expiration date  owned post trans value owned post trans underlying security title  underlying securities value underlying securities direct or indirect own nature indirect own nonderriv transcommon stocks  open market or private salefalsedd filing date  submission nc form  ownership statement of changes in beneficial ownership insider trading  directors officers significant shareholders  issuer macom technology solutions holdings inc mtsi reporting owner van lunsen gil j  director  type title convexer price trans date deemed exe date trans form type trans code eqty swap footnote id trans timelines  shares value total value price  share acq or disp date exercisable expiration date  owned post trans value owned post trans underlying security title  underlying securities value underlying securities direct or indirect own nature indirect own nonderriv transcommon stocka  grant  awardfalsead filing date  submission nc form  ownership statement of changes in beneficial ownership insider trading  directors officers significant shareholders  issuer macom technology solutions holdings inc mtsi reporting owner van lunsen gil j  director  type title convexer price trans date deemed exe date trans form type trans code eqty swap footnote id trans timelines  shares value total value price  share acq or disp date exercisable expiration date  owned post trans value owned post trans underlying security title  underlying securities value underlying securities direct or indirect own nature indirect own nonderriv transcommon stocks  open market or private salefalsedd filing date  submission nc form  ownership statement of changes in beneficial ownership insider trading  directors officers significant shareholders  issuer macom technology solutions holdings inc mtsi reporting owner van lunsen gil j  director  type title convexer price trans date deemed exe date trans form type trans code eqty swap footnote id trans timelines  shares value total value price  share acq or disp date exercisable expiration date  owned post trans value owned post trans underlying security title  underlying securities value underlying securities direct or indirect own nature indirect own nonderriv transcommon stocks  open market or private salefalsedd filing date  submission nc form  ownership statement of changes in beneficial ownership insider trading  directors officers significant shareholders  issuer macom technology solutions holdings inc mtsi reporting owner van lunsen gil j  director  type title convexer price trans date deemed exe date trans form type trans code eqty swap footnote id trans timelines  shares value total value price  share acq or disp date exercisable expiration date  owned post trans value owned post trans underlying security title  underlying securities value underlying securities direct or indirect own nature indirect own nonderriv transcommon stocks  open market or private salefalsedd filing date  submission nc form  ownership statement of changes in beneficial ownership insider trading  directors officers significant shareholders  issuer macom technology solutions holdings inc mtsi reporting owner van lunsen gil j  director  type title convexer price trans date deemed exe date trans form type trans code eqty swap footnote id trans timelines  shares value total value price  share acq or disp date exercisable expiration date  owned post trans value owned post trans underlying security title  underlying securities value underlying securities direct or indirect own nature indirect own nonderriv transcommon stocks  open market or private salefalsedd filing date  submission nc form  ownership statement of changes in beneficial ownership insider trading  directors officers significant shareholders  issuer array biopharma inc arry reporting owner van lunsen gil j  director  type title convexer price trans date deemed exe date trans form type trans code eqty swap footnote id trans timelines  shares value total value price  share acq or disp date exercisable expiration date  owned post trans value owned post trans underlying security title  underlying securities value underlying securities direct or indirect own nature indirect own nonderriv transcommon stockm  exer or conv of deriv security exemptedfalsead derriv transrestricted stock unitsa  grant  awardfalseacommon stockd derriv transstock option right to buya  grant  awardfalseacommon stockd derriv transrestricted stock unitsm  exer or conv of deriv security exemptedfalsedcommon stockd filing date  submission nc form  ownership statement of changes in beneficial ownership insider trading  directors officers significant shareholders  issuer macom technology solutions holdings inc mtsi reporting owner van lunsen gil j  director  type title convexer price trans date deemed exe date trans form type trans code eqty swap footnote id trans timelines  shares value total value price  share acq or disp date exercisable expiration date  owned post trans value owned post trans underlying security title  underlying securities value underlying securities direct or indirect own nature indirect own nonderriv transcommon stocks  open market or private salefalsedd filing date  submission nc form  ownership statement of changes in beneficial ownership insider trading  directors officers significant shareholders  issuer macom technology solutions holdings inc mtsi reporting owner van lunsen gil j  director  type title convexer price trans date deemed exe date trans form type trans code eqty swap footnote id trans timelines  shares value total value price  share acq or disp date exercisable expiration date  owned post trans value owned post trans underlying security title  underlying securities value underlying securities direct or indirect own nature indirect own nonderriv transcommon stocks  open market or private salefalsedd filing date  submission nc form  ownership statement of changes in beneficial ownership insider trading  directors officers significant shareholders  issuer macom technology solutions holdings inc mtsi reporting owner van lunsen gil j  director  type title convexer price trans date deemed exe date trans form type trans code eqty swap footnote id trans timelines  shares value total value price  share acq or disp date exercisable expiration date  owned post trans value owned post trans underlying security title  underlying securities value underlying securities direct or indirect own nature indirect own nonderriv transcommon stocks  open market or private salefalsedd filing date  submission nc form  ownership statement of changes in beneficial ownership insider trading  directors officers significant shareholders  issuer macom technology solutions holdings inc mtsi reporting owner van lunsen gil j  director  type title convexer price trans date deemed exe date trans form type trans code eqty swap footnote id trans timelines  shares value total value price  share acq or disp date exercisable expiration date  owned post trans value owned post trans underlying security title  underlying securities value underlying securities direct or indirect own nature indirect own nonderriv transcommon stocks  open market or private salefalsedd filing date  submission nc form  ownership statement of changes in beneficial ownership insider trading  directors officers significant shareholders  issuer macom technology solutions holdings inc mtsi reporting owner van lunsen gil j  director  type title convexer price trans date deemed exe date trans form type trans code eqty swap footnote id trans timelines  shares value total value price  share acq or disp date exercisable expiration date  owned post trans value owned post trans underlying security title  underlying securities value underlying securities direct or indirect own nature indirect own nonderriv transcommon stocka  grant  awardfalsead filing date  submission nc form  ownership statement of changes in beneficial ownership insider trading  directors officers significant shareholders  issuer array biopharma inc arry reporting owner van lunsen gil j  director  type title convexer price trans date deemed exe date trans form type trans code eqty swap footnote id trans timelines  shares value total value price  share acq or disp date exercisable expiration date  owned post trans value owned post trans underlying security title  underlying securities value underlying securities direct or indirect own nature indirect own derriv transrestricted stock unitsa  grant  awardfalseacommon stockd derriv transstock option right to buya  grant  awardfalseacommon stockd filing date  submission nc form  ownership statement of changes in beneficial ownership insider trading  directors officers significant shareholders  issuer macom technology solutions holdings inc mtsi reporting owner van lunsen gil j  director  type title convexer price trans date deemed exe date trans form type trans code eqty swap footnote id trans timelines  shares value total value price  share acq or disp date exercisable expiration date  owned post trans value owned post trans underlying security title  underlying securities value underlying securities direct or indirect own nature indirect own nonderriv transcommon stocka  grant  awardfalsead filing date  submission nc form  ownership statement of changes in beneficial ownership insider trading  directors officers significant shareholders  issuer macom technology solutions holdings inc mtsi reporting owner van lunsen gil j  director  type title convexer price trans date deemed exe date trans form type trans code eqty swap footnote id trans timelines  shares value total value price  share acq or disp date exercisable expiration date  owned post trans value owned post trans underlying security title  underlying securities value underlying securities direct or indirect own nature indirect own nonderriv transcommon stocka  grant  awardfalsead filing date  submission nc form  ownership statement of changes in beneficial ownership insider trading  directors officers significant shareholders  issuer array biopharma inc arry reporting owner van lunsen gil j  director  type title convexer price trans date deemed exe date trans form type trans code eqty swap footnote id trans timelines  shares value total value price  share acq or disp date exercisable expiration date  owned post trans value owned post trans underlying security title  underlying securities value underlying securities direct or indirect own nature indirect own derriv transstock option right to buya  grant  awardfalseacommon stockd filing date  submission nc form  ownership statement of changes in beneficial ownership insider trading  directors officers significant shareholders  issuer macom technology solutions holdings inc mtsi reporting owner van lunsen gil j  director  type title convexer price trans date deemed exe date trans form type trans code eqty swap footnote id trans timelines  shares value total value price  share acq or disp date exercisable expiration date  owned post trans value owned post trans underlying security title  underlying securities value underlying securities direct or indirect own nature indirect own nonderriv transcommon stocka  grant  awardfalsead filing date  submission nc form  ownership statement of changes in beneficial ownership insider trading  directors officers significant shareholders  issuer macom technology solutions holdings inc mtsi reporting owner van lunsen gil j  director  type title convexer price trans date deemed exe date trans form type trans code eqty swap footnote id trans timelines  shares value total value price  share acq or disp date exercisable expiration date  owned post trans value owned post trans underlying security title  underlying securities value underlying securities direct or indirect own nature indirect own nonderriv transcommon stocka  grant  awardfalsead ←    → db committee composition  macom technology solutions holdings inc home news about us careers investors partner login contact quality mymacom find products rf power products rf power transistors  gan on si rf power transistors  silicon bipolar rf power transistors  silicon mosfet gan and gaas device bias sequencer rf power  silicon bipolar pallet and modules spotlightcomponent optoelectronics laser and modulator drivers transimpedance amplifiers tias clock  data recovery optical post amplifiers ledlaser drivers for display photonic solutions fabryperot lasers distributed feedback lasers photonic integrated circuits pics laser photonic integrated circuits lpicâ„¢ optical subassemblies transmitter optical subassembly tosa receiver optical subassembly rosa amplifiers active splitters amplifier gain blocks catv amplifiers distributed amplifiers fttx amplifiers hybrid amplifiers linear amplifiers low noise amplifiers power amplifiers variable gain amplifiers diodes pin limiter diodes pin switch and attenuator diodes schottky mixer and detector diodes multiplier step recovery diodes varactor tuning diodes germanium tunnel diodes dc voltage current limiter crosspoints and signal conditioners crosspoint switches signal conditionersredrivers sdi products sdi cable drivers sdi cable equalizers sdi reclockers frequency conversion frequency multipliers hybrid mixers mixers receivers transceivers up converters control products cmos switch drivers digital attenuators digital phase shifters iq modulators  demodulators limiters power detectors switches voltage variable attenuators phase detectors passives bias networks couplers filters  diplexers power dividers  combiners transformers  baluns resistor products inductor products capacitors hdcctv devices hdcctv cable drivers hdcctv cable equalizers hdcctv reclockers frequency generation voltage controlled oscillators nltl gaas comb generators communications processors wide area networks voice voip processors carrier convergence processors enterprise voice and data processors hirel components current regulators schottky barrier rectifier chip series silicon switching diodes ultrafast rectifier diodes zener diode chips tc zener reference diodes low noise zener diode silicon zener diodes silicon controlled rectifiers pnp transistors npn power transistors npn rad hard small signal transistors view applications wireless networking and communication wireless network infrastructure wireless backhaul wireless lan wifi satcomvsat g communications optical networking data center metro client side line side fttx rf energy automotive ignition industrial cooking industrial drying medical tumor ablation plasma street lighting aerospace and defense communication ew radar macom in active antennas space and hirel industrial scientific and medical industrial test and measurement healthcare wired broadband catv headend catv hfc infrastructure catvsatellite set top box fttx infrastructure broadcast video cameras distribution amplifiers format conversion monitors routers and switchers enterprise solutions backplane connectivity packet switchers and routers storage area networks transport networksotn surveillance cameras dvrs make purchases explore technologies gallium nitride gan silicon photonics siph silicon germanium sige aluminium gallium arsenide algaas indium phosphide inp gallium arsenide gaas silicon si heterolithic microwave integrated circuit hmic self aligning etched facet technology get support training rf  microwave product selection guide contact us key markets  products brochure technical resources library optoelectronics  photonics portfolio high power gan portfolio sdi video portfolio diodes portfolio space  highreliability portfolio committee composition show all john ocampo chairman john ocampo has served as a director and as the chairman of the board of directors since our inception in march  mr ocampo has also served as president of gaas labs since cofounding it in february  previously mr ocampo cofounded sirenza in  served as a director of sirenza from its inception in  through its sale to rfmd in november  and served in a number of senior executive roles throughout that period most recently as its chairman from december  through november  mr ocampo also served as a director of rfmd from november  to november  from october  to october  mr ocampo served as a director of ubiquiti networks inc “ubiquiti” a developer of networking technology for service providers and enterprises mr ocampo also serves as a director of various privatelyheld companies mr ocampo holds a bsee from santa clara university mr ocampo’s strategic vision developed over more than  years successfully leading public and private companies in the rf semiconductor and component industry is a unique asset to our board of directors his engineering background and extensive knowledge of our operations markets and technology provides our board of directors with important insights we also believe that having our largest stockholder together with mrs ocampo and their affiliates on the board of directors assists the board in making decisions aimed at increasing stockholder value over the long term john croteau president  chief executive officer and director john croteau has served as our chief executive officer and as a director since december  and as our president since october  mr croteau joined us from nxp semiconductors nv “nxp” a provider of mixed signal solutions and standard products where he served as the senior vice president and general manager of its highperformance rf business from may  to october  for three of those years mr croteau also managed nxp’s power  lighting solutions business prior to joining nxp mr croteau held numerous product management positions at analog devices inc “adi” a highperformance semiconductor company including general manager for adi’s convergent platforms and services group as well as product line director for the integrated audio group mr croteau holds a bs in engineering science and mechanics from penn state university mr croteau’s qualifications to serve as a director include his unique perspective and insights into our operations as our current president and chief executive officer including his knowledge of our products technologies business relationships competitive and financial positioning senior leadership and strategic opportunities and challenges our board of directors also benefits from mr croteau’s industry perspective stemming from his broad experience in a variety of executive roles at public semiconductor companies charles bland director charles bland has served as a director since june  and previously served as a director from december  to february  mr bland served as our chief executive officer from february  to december  and was employed by us in a transitional capacity following his retirement from service as our chief executive officer through may  mr bland previously served as our chief operating officer from june  to february  from april  through december  mr bland served as a director and as the chairman of the audit committee of nighthawk radiology holdings inc “nighthawk” a provider of teleradiology services during  mr bland served as the chief financial officer of american gaming systems a privatelyheld designer manufacturer and operator of gaming machines mr bland served as the chief financial officer of sirenza microdevices inc “sirenza” a supplier of radio frequency semiconductors and related components for the commercial communications consumer and aerospace defense and homeland security equipment markets from july  through its sale to rf micro devices inc “rfmd” in november  and also as its chief operating officer from may  until july  mr bland received his bs in accounting and finance from the ohio state university and his mba from the sloan school massachusetts institute of technology mr bland’s qualifications to serve as a director include his detailed knowledge of our business operations senior leadership and strategic opportunities and challenges based on his prior service as our chief executive officer and chief operating officer in addition mr bland’s extensive experience in a variety of executive roles at public companies in our industry his executive experience in other industries and his prior experience as a public company director and audit committee chair allow him to bring a broad and diverse perspective to our board of directors his prior chief financial officer and audit committee experience have provided him expertise with accounting principles and financial reporting rules and regulations in evaluating financial results and in generally overseeing the financial reporting process member of the audit committee chair of the nominating and governance committee peter chung independent director peter chung has served as a director since december  mr chung is a managing director and the chief executive officer of summit partners lp which he joined in august  mr chung currently serves as a director and the chairman of the compensation committee of a networks inc a provider of application networking technologies and as a director and chairman of the nominating and corporate governance committee of acacia communications inc a provider of highspeed coherent optical interconnect products  mr chung has also served as a director of numerous other public companies including most recently ubiquiti from march  to october  nighthawk from march  to december  seabright holdings inc a provider of multijurisdictional workers’ compensation insurance and general liability insurance from october  to may  and sirenza from october  to april  mr chung also serves as a director of several privatelyheld companies mr chung received an ab from harvard university and an mba from stanford university mr chung is an experienced investor in marketleading growth companies he contributes broadbased knowledge and experience in business strategy capital markets and the communications technology and semiconductor industries mr chung provides valuable insight to our board of directors on all matters facing us from operational to strategic  member of the nominating and governance committee chair of the compensation committee gil van lunsen independent director gil van lunsen has served as a director since august  prior to his retirement in june  mr van lunsen was a managing partner of kpmg llp and led the firm’s tulsa oklahoma office during his year career mr van lunsen held various positions of increasing responsibility with kpmg llp and was elected partner in  mr van lunsen is currently a member of the board of directors and the audit committee chairman at array biopharma inc a biopharmaceutical company he served as a director and the chairman of the audit committee of oneok partners lp a natural gas gathering processing storage and transportation provider and its predecessor entities from  until his retirement in  previously mr van lunsen served as a director of sirenza and was chairman of its audit committee from october  through its sale to rfmd in november  mr van lunsen received a bsba in accounting from the university of denver mr van lunsen has extensive experience with complex financial and accounting issues and as a former partner of kpmg llp and the audit committee chairman at other public companies in our industry and others provides valuable leadership and insights to our board of directors on accounting financial and governance matters having served as a director of sirenza mr van lunsen has also developed strong domain knowledge of the operational and financial issues facing our company and our industry  chair of the audit committee member of the nominating and governance committee member of the compensation committee susan ocampo director susan ocampo has served as a director since june  and previously served as a director from december  to february  she has also served as vice president secretary and treasurer of gaas labs llc “gaas labs” a private investment fund targeting the communications semiconductor market since cofounding it in february  previously mrs ocampo cofounded sirenza in  mrs ocampo served as sirenza’s treasurer from november  through its sale to rfmd in november  mrs ocampo holds a ba from maryknoll college mrs ocampo’s extensive experience investing and serving in financial leadership roles with semiconductor companies strengthens our board of director’s oversight of our enterprise risk management treasury functions and internal financial controls we also believe that having our largest stockholder together with mr ocampo and their affiliates on the board of directors assists the board in making decisions aimed at increasing stockholder value over the long term stephen g daly director stephen g daly has served as a director since march   from january  through march  mr daly served as the president of hittite microwave corporation “hittite” a provider of analog and mixed signal integrated circuits modules and subsystems for commercial and military rf microwave and millimeterwave applications mr daly also served as hittite’s chief executive officer from december  through march   he served as a member of hittites board of directors from january  through may  and as its chairman from december  through march  from  to  he was employed in other application engineering marketing and sales roles at hittite mr daly also serves as a director of a privatelyheld company  mr daly received a bs in electrical engineering from northeastern university  mr daly’s depth and breadth of expertise in the analog and mixed signal semiconductor industry and prior experience serving on the board of directors of a public company in our industry contributes valuable perspective and insight to our board of directors  member of the audit committee member of the compensation committee geoffrey g ribar director geoffrey g ribar has served as a director since march  mr ribar has served as senior vice president and chief financial officer of cadence design systems inc a provider of system design tools software intellectual property and services since november    previously he served as chief financial officer for a number of semiconductor companies including telegent systems inc sirf technology inc asyst technology inc matrix semiconductor inc and nvidia corporation he received his bs degree in chemistry and an mba from the university of michigan mr ribar provides our board of directors with financial and accounting expertise based on his experience as a chief financial officer as well as semiconductor industry expertise in areas ranging from global finance and mergers and acquisitions to investor relations member of the audit committee display all bios   audit nominating and governance compensation charles bland charles bland director charles bland has served as a director since june  and previously served as a director from december  to february  mr bland served as our chief executive officer from february  to december  and was employed by us in a transitional capacity following his retirement from service as our chief executive officer through may  mr bland previously served as our chief operating officer from june  to february  from april  through december  mr bland served as a director and as the chairman of the audit committee of nighthawk radiology holdings inc “nighthawk” a provider of teleradiology services during  mr bland served as the chief financial officer of american gaming systems a privatelyheld designer manufacturer and operator of gaming machines mr bland served as the chief financial officer of sirenza microdevices inc “sirenza” a supplier of radio frequency semiconductors and related components for the commercial communications consumer and aerospace defense and homeland security equipment markets from july  through its sale to rf micro devices inc “rfmd” in november  and also as its chief operating officer from may  until july  mr bland received his bs in accounting and finance from the ohio state university and his mba from the sloan school massachusetts institute of technology mr bland’s qualifications to serve as a director include his detailed knowledge of our business operations senior leadership and strategic opportunities and challenges based on his prior service as our chief executive officer and chief operating officer in addition mr bland’s extensive experience in a variety of executive roles at public companies in our industry his executive experience in other industries and his prior experience as a public company director and audit committee chair allow him to bring a broad and diverse perspective to our board of directors his prior chief financial officer and audit committee experience have provided him expertise with accounting principles and financial reporting rules and regulations in evaluating financial results and in generally overseeing the financial reporting process   peter chung peter chung independent director peter chung has served as a director since december  mr chung is a managing director and the chief executive officer of summit partners lp which he joined in august  mr chung currently serves as a director and the chairman of the compensation committee of a networks inc a provider of application networking technologies and as a director and chairman of the nominating and corporate governance committee of acacia communications inc a provider of highspeed coherent optical interconnect products  mr chung has also served as a director of numerous other public companies including most recently ubiquiti from march  to october  nighthawk from march  to december  seabright holdings inc a provider of multijurisdictional workers’ compensation insurance and general liability insurance from october  to may  and sirenza from october  to april  mr chung also serves as a director of several privatelyheld companies mr chung received an ab from harvard university and an mba from stanford university mr chung is an experienced investor in marketleading growth companies he contributes broadbased knowledge and experience in business strategy capital markets and the communications technology and semiconductor industries mr chung provides valuable insight to our board of directors on all matters facing us from operational to strategic    gil van lunsen gil van lunsen independent director gil van lunsen has served as a director since august  prior to his retirement in june  mr van lunsen was a managing partner of kpmg llp and led the firm’s tulsa oklahoma office during his year career mr van lunsen held various positions of increasing responsibility with kpmg llp and was elected partner in  mr van lunsen is currently a member of the board of directors and the audit committee chairman at array biopharma inc a biopharmaceutical company he served as a director and the chairman of the audit committee of oneok partners lp a natural gas gathering processing storage and transportation provider and its predecessor entities from  until his retirement in  previously mr van lunsen served as a director of sirenza and was chairman of its audit committee from october  through its sale to rfmd in november  mr van lunsen received a bsba in accounting from the university of denver mr van lunsen has extensive experience with complex financial and accounting issues and as a former partner of kpmg llp and the audit committee chairman at other public companies in our industry and others provides valuable leadership and insights to our board of directors on accounting financial and governance matters having served as a director of sirenza mr van lunsen has also developed strong domain knowledge of the operational and financial issues facing our company and our industry  stephen g daly stephen g daly director stephen g daly has served as a director since march   from january  through march  mr daly served as the president of hittite microwave corporation “hittite” a provider of analog and mixed signal integrated circuits modules and subsystems for commercial and military rf microwave and millimeterwave applications mr daly also served as hittite’s chief executive officer from december  through march   he served as a member of hittites board of directors from january  through may  and as its chairman from december  through march  from  to  he was employed in other application engineering marketing and sales roles at hittite mr daly also serves as a director of a privatelyheld company  mr daly received a bs in electrical engineering from northeastern university  mr daly’s depth and breadth of expertise in the analog and mixed signal semiconductor industry and prior experience serving on the board of directors of a public company in our industry contributes valuable perspective and insight to our board of directors    geoffrey g ribar geoffrey g ribar director geoffrey g ribar has served as a director since march  mr ribar has served as senior vice president and chief financial officer of cadence design systems inc a provider of system design tools software intellectual property and services since november    previously he served as chief financial officer for a number of semiconductor companies including telegent systems inc sirf technology inc asyst technology inc matrix semiconductor inc and nvidia corporation he received his bs degree in chemistry and an mba from the university of michigan mr ribar provides our board of directors with financial and accounting expertise based on his experience as a chief financial officer as well as semiconductor industry expertise in areas ranging from global finance and mergers and acquisitions to investor relations      chair  member  independent director about macom macom technology solutions holdings inc wwwmacomcom supplies key enabling technologies for the cloud connected apps economy and modern networked battlefield learn more corporate documents corporate presentation cloud data center forum slides preliminary injunction order appliedmicro acquisition slides macom analyst day presentation nongaap proforma data for auto sale aeroflexmetelics acquisition slides fibest acquisition slides binoptics acquisition presentation mindspeed acquisition slides shareholder tools shareholder briefcase corporate presentation download library snapshot rss feeds macomtweets tweets by macomtweets stock quote nasdaqmtsi price  change  day high  day low  volume   pm et on jul   delayed at least  minutes provided by esignal investor relations news  events news releases events  webcasts corporate governance leadership board of directors committee composition governance documents financial information financial reports sec filings irs forms stock information analyst coverage investor faqs request information email alerts investor contacts events  webcasts aug   at  pm et macom technology solutions third quarter fiscal  financial results conference call view all events  webcasts » products rf power products optoelectronics photonic solutions optical subassemblies amplifiers diodes crosspoints and signal conditioners sdi products frequency conversion control products passives hdcctv devices frequency generation communications processors hirel components applications wireless networking and communication optical networking rf energy aerospace and defense industrial scientific and medical wired broadband broadcast video enterprise solutions surveillance about macom investors in the community news and events careers quality  reliability virtual patent marking foundry california transparency in supply chains act support training rf  microwave product selection guide contact us key markets  products brochure technical resources library optoelectronics  photonics portfolio high power gan portfolio sdi video portfolio diodes portfolio space  highreliability portfolio   macom all rights reserved sitemap  privacy policy  terms of use array biopharma inc arryo people  reuterscom x edition united states africa américa latina عربي argentina brasil canada  deutschland españa france india italia  méxico россия united kingdom united states array biopharma inc arryo related topics stocksstock screenermarket datahealthcarebiotechnology  medical research overview news key developments people charts financials analysts research pulse arryo on consolidated issue listed on nasdaq global market usd  jul  change  chg   prev close  open  days high  days low  volume  avg vol  wk high  wk low  summary name age since current position kyle lefkoff   independent chairman of the board ron squarer   chief executive officer director jason haddock   chief financial officer andrew robbins   chief operating officer nicholas saccomano   chief scientific officer john moore   vice president general counsel secretary victor sandor   chief medical officer shalini sharp   director charles baum   independent director gwendolyn fyfe   independent director john orwin   independent director gil van lunsen   independent director tricia haugeto  director corporate communications and investor relations » insider trading biographies name description kyle lefkoff mr kyle a lefkoff is an independent chairman of the board of array biopharma inc from january  through april  mr lefkoff served as our interim executive chairman following the resignation of our former chief executive officer mr robert e conway in january  when our current chief executive officer mr ron squarer was hired in april  mr lefkoff stepped down as executive chairman and resumed his position as chairman of our board of directors since  mr lefkoff has been a general partner of boulder ventures ltd a venture capital firm and a founding investor in our company from  until  mr lefkoff was employed by colorado venture management a venture capital firm mr lefkoff serves on the board of directors for a number of private companies including miragen therapeutics market force information and commercialtribe inc ron squarer mr ron squarer serves as chief executive officer director of array biopharma inc prior to array prior to array mr squarer served as senior vice president chief commercial officer at hospira inc a global pharmaceutical and medical device company from february  to april  where he was responsible for delivering  billion in annual revenue and leading more than  employees worldwide from  to  mr squarer was responsible for strategy new product development and commercialization acquisitions partnerships and portfolio prioritization as senior vice president global marketing and corporate development and held a similar role focused on strategy and business development from  to  mr squarer joined hospira from mayne pharma an australiabased specialty injectable pharmaceutical company where he served as senior vice president global corporate and business development from  to  when mayne was sold to hospira for  billion in  prior to  mr squarer held senior management roles at both pfizer inc focused on global oncology commercial development and at smithkline beecham pharmaceuticals now glaxosmithkline in the us and europe jason haddock mr jason haddock is chief financial officer of the company from november  to january  mr haddock held leadership positions of increasing responsibility at bristolmyers squibb in a variety of accounting planning commercial analytical and business development capacities for highgrowth business units including head of finance for the worldwide commercialization and medical divisions mr haddock has served as cfo and coo for highgrowth business units in asia pacific europe and the united states he mostly recently served as cfo and coo at berg health a privately held boston biopharmaceutical company from june  to july  andrew robbins mr andrew r robbins is chief operating officer of company from july  he was our senior vice president commercial operations mr robbins has extensive commercial development and strategic leadership expertise from a year career in the pharmaceutical industry with a specific focus on oncologyhematology products from january  to july  he held management positions at hospira inc a global pharmaceutical and medical device company including general managervice president of the us alternate site business unit and vice president of corporate development prior to joining array mr robbins also served on the board of directors of fate therapeutics cytograft and stemcor systems all venturebacked health care companies prior to january  he held commercial leadership positions within pfizers oncology unit nicholas saccomano dr nicholas a saccomano phd is chief scientific officer of the company he has  years of experience in pharmaceutical and biotechnology research and development with expertise in discovery research clinical development portfolio strategy technology and clinical candidate licensing and scientific partnering dr saccomano most recently served as chief technology officer at somalogic inc headquartered in boulder colorado from january  to may  and as a consultant for somalogic from june  to december  prior to joining somalogic dr saccomano served as chief scientific officer at bend research inc headquartered in bend oregon from may  to december  and as a consultant for bend research from january  to december  and continued on their board of directors until october  dr saccomano also held positions of increasing responsibility at pfizer inc from december  to may  including senior vice president in the rd organization and vice president of discovery technology as head of discovery technology he managed and developed a diverse set of enabling technologies used broadly across the drug discovery pipeline during his tenure at pfizer he also directed medicinal sciences drug discovery and strategic alliances john moore mr john r moore is vice president general counsel secretary of array biopharma inc prior to joining array mr moore was an associate for three years with the law firm of wilson sonsini goodrich  rosati where he negotiated transactions involving technology intellectual property and products from september  to july  and august  to june  mr moore was an associate with the law firms of kenyon  kenyon and arnold white  durkee respectively where he focused on intellectual property matters he currently serves on the board of directors of nivalis therapeutics inc a public company victor sandor dr victor sandor md has been appointed as chief medical officer of the company prior to joining array dr sandor was senior vice president for global clinical development at incyte corporation a position he held beginning may  after first joining incyte in february  as its vice president global oncology drug development prior to joining incyte dr sandor was vice president and chief medical officer for oncology at biogen idec from november  to february  he previously held positions of increasing responsibility in oncology product development at astrazeneca from september  to november  where he played an important role in the registration of arimidex for adjuvant use the development of faslodex and the development of several early stage programs through proof of concept shalini sharp ms shalini sharp has been appointed as director of the company effective april   ms sharp has served as chief financial officer of ultragenyx pharmaceutical inc a publiclytraded biopharmaceutical company focused on rare diseases since  where she is responsible for leading the corporate finance strategy and information technology functions and is a member of the company’s executive leadership team ms sharp is also a member of the board of directors of agenus inc formerly antigenics inc a publicly traded immunooncology company where she served as chief financial officer from  to  she joined agenus in  and held increasing roles of responsibility spanning strategic planning corporate development investor relations corporate finance and business development she is also a member of the board of directors of the tb alliance a nonprofit organization dedicated to the development and distribution of treatments for tuberculosis in the developing world prior to agenus ms sharp held similar roles at elan pharmaceuticals from  to  including serving as chief of staff to the chairman of the board of directors during that companys restructuring she has spearheaded numerous financing and business development transactions that were critical to the success of agenus and elan ms sharp was also a management consultant at mckinsey  company as well as an investment banker at goldman sachs specializing in pharmaceuticals and medical devices ms sharp holds both a ba magna cum laude and a mba from harvard university charles baum dr charles m baum md phd is an independent director of the company dr baum has served as the president and chief executive officer of mirati therapeutics since  prior to joining mirati dr baum had worked at pfizer since  most recently as the senior vice president for clinical research within pfizers worldwide research  development division at pfizer dr baum held roles of increasing responsibility including vice president and head of oncology development and chief medical officer for pfizers biotherapeutics and bioinnovation center a pfizer division comprised of small biotech research units during his tenure at pfizer he was responsible for the development of the company’s oncology portfolio including the tyrosine kinase inhibitors sutent® sunitinib inlyta® axitinib and xalkori® crizotinib prior to joining pfizer dr baum was responsible for the phase iiv development of several oncology compounds at scheringplough including temodar® temozolomide gwendolyn fyfe dr gwendolyn a fyfe md is an independent director of the company from  to  dr fyfe held various positions with genentech inc now a member of the roche group including vice president oncology development vice president avastin® franchise team as well as the honorary title of senior staff scientist dr fyfe played an important role in the development of genentechs approved oncology agents including rituxan® herceptin® avastin® and tarceva® dr fyfe sat on the development oversight committee for all of genentechs products and participated in the research review committee that moved products from research into clinical development since leaving genentech in  dr fyfe has been a consultant for venture capital firms and for a variety of biotechnology companies dr fyfe serves as a director of publiclytraded infinity pharmaceuticals and igenica biotherapeutics a private company dr fyfe is a recognized oncology expert in the broader oncology community and has been an invited member of institute of medicine panels national cancer institute working groups and grant committees and american society of clinical oncologists oversight committees john orwin mr john a orwin is an independent director of array biopharma inc he became chief executive officer of relypsa inc in june  from february  to may  mr orwin served as chief executive officer of affymax inc which he joined in april  as president and chief operating officer from january  to april  mr orwin served at genentech where he served as senior vice president biooncology business unit since  from  to  mr orwin served in various executive level positions at johnson  johnson prior to that mr orwin was senior director oncology marketing at alza pharmaceuticals acquired by johnson  johnson vice president marketing at sangstat medical corporation marketing director asthma at rhonepoulenc rorer pharmaceuticals and product manager schering oncologybiotech at scheringplough corporation mr orwin serves on the board of directors of publiclytraded relypsa inc and seattle genetics inc gil van lunsen mr gil j van lunsen is an independent director of array biopharma inc prior to his retirement in june  mr van lunsen was an office managing partner of kpmg llp and led the firms tulsa oklahoma office during his year career mr van lunsen held various positions of increasing responsibility within kpmg and was elected to the partnership in  until april  mr van lunsen was the chairman of both the audit committee and the conflicts committee at oneok partners gp llc in tulsa oklahoma additionally mr van lunsen is currently the audit committee chairman and a member of the governance committee and compensation committee at macom technology solutions inc in lowell massachusetts tricia haugeto basic compensation name fiscal year total kyle lefkoff  ron squarer  jason haddock  andrew robbins  nicholas saccomano  john moore  victor sandor  shalini sharp  charles baum  gwendolyn fyfe  john orwin  gil van lunsen  tricia haugeto  as of   jun  options compensation name options value kyle lefkoff   ron squarer   jason haddock   andrew robbins   nicholas saccomano   john moore   victor sandor   shalini sharp   charles baum   gwendolyn fyfe   john orwin   gil van lunsen   tricia haugeto   insider trading name shares traded price sandor victor   saccomano nicholas a   squarer ron r   saccomano nicholas a   moore john r   moore john r   robbins andrew r   robbins andrew r   sandor victor   squarer ron r   lefkoff kyle a   lefkoff kyle a   lefkoff kyle a   baum charles m   baum charles m   lefkoff kyle a   baum charles m   van lunsen gil j   orwin john a   fyfe gwen a   lefkoff kyle a   redmile group llc   sandor victor   sandor victor   redmile group llc   » full list on insider trading related topics stocksstock screenermarket datahealthcarebiotechnology  medical research